NDA Partners LLC: A Development Partner to Biopharmaceutical Investors and Companies

Bruce Burlington, MD

Practice Area Focus

  • Pharmaceuticals
  • Medical Devices
  • Diagnostics
  • Development Strategy
  • Regulatory Strategy
  • Drug Safety


Bruce Burlington, MD joined NDA Partners as a Premier Expert Consultant in 2007. He provides strategic guidance on pharmaceutical product development and regulatory affairs including preparation for FDA and Advisory Committees meetings. Dr. Burlington was previously Executive Vice President of Regulatory Affairs, Audit, Compliance, Human Safety, and Quality at Wyeth. Before joining Wyeth in 1999, he had served at the US Food & Drug Administration (FDA) since 1981, including as Director of CDRH, Medical Deputy Director of CDER, and Head of Biologics IND in CBER. He has also been on the Board of Directors, Audit and Science Committees (Chair), at Cangene and AstraZeneca as well as serving on corporate advisory committees at Lumbeck and Sanofi.